147 related articles for article (PubMed ID: 31871269)
1. Mechanisms of Entrectinib Resistance in a Neuroblastoma Xenograft Model.
MacFarland SP; Naraparaju K; Iyer R; Guan P; Kolla V; Hu Y; Tan K; Brodeur GM
Mol Cancer Ther; 2020 Mar; 19(3):920-926. PubMed ID: 31871269
[TBL] [Abstract][Full Text] [Related]
2. Entrectinib is a potent inhibitor of Trk-driven neuroblastomas in a xenograft mouse model.
Iyer R; Wehrmann L; Golden RL; Naraparaju K; Croucher JL; MacFarland SP; Guan P; Kolla V; Wei G; Cam N; Li G; Hornby Z; Brodeur GM
Cancer Lett; 2016 Mar; 372(2):179-86. PubMed ID: 26797418
[TBL] [Abstract][Full Text] [Related]
3. Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastoma.
Pacenta HL; Macy ME
Drug Des Devel Ther; 2018; 12():3549-3561. PubMed ID: 30425456
[TBL] [Abstract][Full Text] [Related]
4. Combating autophagy is a strategy to increase cytotoxic effects of novel ALK inhibitor entrectinib in neuroblastoma cells.
Aveic S; Pantile M; Seydel A; Esposito MR; Zanon C; Li G; Tonini GP
Oncotarget; 2016 Feb; 7(5):5646-63. PubMed ID: 26735175
[TBL] [Abstract][Full Text] [Related]
5. Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor.
Menichincheri M; Ardini E; Magnaghi P; Avanzi N; Banfi P; Bossi R; Buffa L; Canevari G; Ceriani L; Colombo M; Corti L; Donati D; Fasolini M; Felder E; Fiorelli C; Fiorentini F; Galvani A; Isacchi A; Borgia AL; Marchionni C; Nesi M; Orrenius C; Panzeri A; Pesenti E; Rusconi L; Saccardo MB; Vanotti E; Perrone E; Orsini P
J Med Chem; 2016 Apr; 59(7):3392-408. PubMed ID: 27003761
[TBL] [Abstract][Full Text] [Related]
6. Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer.
Ku BM; Bae YH; Lee KY; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Invest New Drugs; 2020 Apr; 38(2):360-368. PubMed ID: 31124056
[TBL] [Abstract][Full Text] [Related]
7. Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications.
Ardini E; Menichincheri M; Banfi P; Bosotti R; De Ponti C; Pulci R; Ballinari D; Ciomei M; Texido G; Degrassi A; Avanzi N; Amboldi N; Saccardo MB; Casero D; Orsini P; Bandiera T; Mologni L; Anderson D; Wei G; Harris J; Vernier JM; Li G; Felder E; Donati D; Isacchi A; Pesenti E; Magnaghi P; Galvani A
Mol Cancer Ther; 2016 Apr; 15(4):628-39. PubMed ID: 26939704
[TBL] [Abstract][Full Text] [Related]
8. TrkB inhibition by GNF-4256 slows growth and enhances chemotherapeutic efficacy in neuroblastoma xenografts.
Croucher JL; Iyer R; Li N; Molteni V; Loren J; Gordon WP; Tuntland T; Liu B; Brodeur GM
Cancer Chemother Pharmacol; 2015 Jan; 75(1):131-41. PubMed ID: 25394774
[TBL] [Abstract][Full Text] [Related]
9. Antitumor Activity of Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor, in
Smith KM; Fagan PC; Pomari E; Germano G; Frasson C; Walsh C; Silverman I; Bonvini P; Li G
Mol Cancer Ther; 2018 Feb; 17(2):455-463. PubMed ID: 29237803
[TBL] [Abstract][Full Text] [Related]
10. Foretinib Overcomes Entrectinib Resistance Associated with the
Nishiyama A; Yamada T; Kita K; Wang R; Arai S; Fukuda K; Tanimoto A; Takeuchi S; Tange S; Tajima A; Furuya N; Kinoshita T; Yano S
Clin Cancer Res; 2018 May; 24(10):2357-2369. PubMed ID: 29463555
[No Abstract] [Full Text] [Related]
11. Entrectinib: a potent new TRK, ROS1, and ALK inhibitor.
Rolfo C; Ruiz R; Giovannetti E; Gil-Bazo I; Russo A; Passiglia F; Giallombardo M; Peeters M; Raez L
Expert Opin Investig Drugs; 2015; 24(11):1493-500. PubMed ID: 26457764
[TBL] [Abstract][Full Text] [Related]
12. Effect of CEP-751 (KT-6587) on neuroblastoma xenografts expressing TrkB.
Evans AE; Kisselbach KD; Liu X; Eggert A; Ikegaki N; Camoratto AM; Dionne C; Brodeur GM
Med Pediatr Oncol; 2001 Jan; 36(1):181-4. PubMed ID: 11464878
[TBL] [Abstract][Full Text] [Related]
13. Trk inhibitor attenuates the BDNF/TrkB-induced protection of neuroblastoma cells from etoposide in vitro and in vivo.
Li Z; Zhang Y; Tong Y; Tong J; Thiele CJ
Cancer Biol Ther; 2015; 16(3):477-83. PubMed ID: 25700942
[TBL] [Abstract][Full Text] [Related]
14. GZD2202, a novel TrkB inhibitor, suppresses BDNF-mediated proliferation and metastasis in neuroblastoma models.
Zou J; Zhang Z; Xu F; Cui S; Qi C; Luo J; Wang Z; Lu X; Tu Z; Ren X; Song L; Ding K
J Drug Target; 2019 Apr; 27(4):442-450. PubMed ID: 30301369
[TBL] [Abstract][Full Text] [Related]
15. Neuropeptide Y receptor Y5 as an inducible pro-survival factor in neuroblastoma: implications for tumor chemoresistance.
Czarnecka M; Trinh E; Lu C; Kuan-Celarier A; Galli S; Hong SH; Tilan JU; Talisman N; Izycka-Swieszewska E; Tsuei J; Yang C; Martin S; Horton M; Christian D; Everhart L; Maheswaran I; Kitlinska J
Oncogene; 2015 Jun; 34(24):3131-43. PubMed ID: 25132261
[TBL] [Abstract][Full Text] [Related]
16. Entrectinib Induces Apoptosis and Inhibits the Epithelial-Mesenchymal Transition in Gastric Cancer with NTRK Overexpression.
Sohn SH; Sul HJ; Kim BJ; Kim HS; Zang DY
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008821
[TBL] [Abstract][Full Text] [Related]
17. Entrectinib reverses cytostatic resistance through the inhibition of ABCB1 efflux transporter, but not the CYP3A4 drug-metabolizing enzyme.
Vagiannis D; Yu Z; Novotna E; Morell A; Hofman J
Biochem Pharmacol; 2020 Aug; 178():114061. PubMed ID: 32497550
[TBL] [Abstract][Full Text] [Related]
18. Molecular Iodine/Cyclophosphamide Synergism on Chemoresistant Neuroblastoma Models.
Álvarez-León W; Mendieta I; Delgado-González E; Anguiano B; Aceves C
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445656
[TBL] [Abstract][Full Text] [Related]
19. Small molecule inhibitor agerafenib effectively suppresses neuroblastoma tumor growth in mouse models via inhibiting ERK MAPK signaling.
Li H; Yu Y; Zhao Y; Wu D; Yu X; Lu J; Chen Z; Zhang H; Hu Y; Zhai Y; Su J; Aheman A; De Las Casas A; Jin J; Xu X; Shi Z; Woodfield SE; Vasudevan SA; Agarwal S; Yan Y; Yang J; Foster JH
Cancer Lett; 2019 Aug; 457():129-141. PubMed ID: 31100410
[TBL] [Abstract][Full Text] [Related]
20. Brain-derived neurotrophic factor activation of TrkB protects neuroblastoma cells from chemotherapy-induced apoptosis via phosphatidylinositol 3'-kinase pathway.
Jaboin J; Kim CJ; Kaplan DR; Thiele CJ
Cancer Res; 2002 Nov; 62(22):6756-63. PubMed ID: 12438277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]